Allogene Therapeutics Inc
ALLO1.395USD
-0.075-5.10%
Market hours （ET）Quotes delayed by 15 min
311.31MMarket Cap
LossP/E TTM
More Details of Allogene Therapeutics Inc Company
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Allogene Therapeutics Inc Info
Ticker SymbolALLO
Company nameAllogene Therapeutics Inc
IPO dateOct 11, 2018
CEOChang (David D)
Number of employees226
Security typeOrdinary Share
Fiscal year-endOct 11
Address210 East Grand Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504572700
Websitehttps://allogene.com/
Ticker SymbolALLO
IPO dateOct 11, 2018
CEOChang (David D)
Company Executives of Allogene Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.56M
--
Dr. David D Chang, M.D., Ph.D.
Dr. David D Chang, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.73M
+0.08%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
441.42K
-7.68%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
303.06K
--
Mr. Owen N. Witte, M.D.
Mr. Owen N. Witte, M.D.
Independent Director
Independent Director
292.83K
+14.59%
Mr. Benjamin Machinas (Ben) Beneski
Mr. Benjamin Machinas (Ben) Beneski
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
217.72K
-0.36%
Mr. Earl Martin Douglas, Esq.
Mr. Earl Martin Douglas, Esq.
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary
110.21K
-5.49%
Dr. Zachary Roberts, M.D., Ph.D.
Dr. Zachary Roberts, M.D., Ph.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
101.90K
-38.68%
Ms. Deborah M. (Debbie) Messemer
Ms. Deborah M. (Debbie) Messemer
Independent Director
Independent Director
45.96K
-44.53%
Mr. Todd B. Sisitsky
Mr. Todd B. Sisitsky
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.56M
--
Dr. David D Chang, M.D., Ph.D.
Dr. David D Chang, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
5.73M
+0.08%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
441.42K
-7.68%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
303.06K
--
Mr. Owen N. Witte, M.D.
Mr. Owen N. Witte, M.D.
Independent Director
Independent Director
292.83K
+14.59%
Mr. Benjamin Machinas (Ben) Beneski
Mr. Benjamin Machinas (Ben) Beneski
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
217.72K
-0.36%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Pfizer Inc
9.80%
TPG Capital, L.P.
8.33%
Citadel Advisors LLC
6.22%
BlackRock Institutional Trust Company, N.A.
4.96%
The Vanguard Group, Inc.
4.01%
Other
66.67%
Shareholders
Shareholders
Proportion
Pfizer Inc
9.80%
TPG Capital, L.P.
8.33%
Citadel Advisors LLC
6.22%
BlackRock Institutional Trust Company, N.A.
4.96%
The Vanguard Group, Inc.
4.01%
Other
66.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.53%
Hedge Fund
14.88%
Private Equity
12.68%
Investment Advisor/Hedge Fund
10.87%
Corporation
9.80%
Individual Investor
6.87%
Research Firm
2.67%
Venture Capital
1.14%
Family Office
0.17%
Other
20.38%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
373
141.70M
82.47%
+102.89K
2025Q3
399
141.90M
86.43%
-23.30M
2025Q2
398
162.31M
93.64%
-14.10M
2025Q1
416
176.74M
92.40%
-25.25M
2024Q4
410
168.35M
94.70%
-249.19K
2024Q3
421
168.58M
93.61%
-350.08K
2024Q2
427
169.46M
77.53%
+34.30M
2024Q1
428
135.12M
90.51%
-19.16M
2023Q4
437
125.49M
95.40%
-8.43M
2023Q3
439
133.73M
100.61%
-3.22M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Pfizer Inc
22.03M
9.93%
--
--
Jun 30, 2025
TPG Capital, L.P.
18.72M
8.44%
--
--
Jun 30, 2025
Citadel Advisors LLC
13.35M
6.01%
+3.09M
+30.17%
Jul 09, 2025
BlackRock Institutional Trust Company, N.A.
11.31M
5.1%
+500.60K
+4.63%
Jun 30, 2025
The Vanguard Group, Inc.
8.26M
3.72%
+191.57K
+2.37%
Jun 30, 2025
Belldegrun (Arie S)
7.56M
3.41%
--
--
Jun 30, 2025
PRIMECAP Management Company
5.72M
2.58%
+787.30K
+15.96%
Jun 30, 2025
Two Sigma Investments, LP
3.40M
1.53%
-872.24K
-20.40%
Jun 30, 2025
Chang (David D)
5.72M
2.58%
--
--
Jun 30, 2025
Woodline Partners LP
4.36M
1.97%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
WisdomTree BioRevolution Fund
0.7%
Virtus LifeSci Biotech Clinical Trials ETF
0.6%
Invesco NASDAQ Future Gen 200 ETF
0.59%
Global X Genomics & Biotechnology ETF
0.2%
Zacks Small/Mid Cap ETF
0.13%
iShares Health Innovation Active ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
View more
WisdomTree BioRevolution Fund
Proportion0.7%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.6%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.59%
Global X Genomics & Biotechnology ETF
Proportion0.2%
Zacks Small/Mid Cap ETF
Proportion0.13%
iShares Health Innovation Active ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Allogene Therapeutics Inc?
The top five shareholders of Allogene Therapeutics Inc are:
Pfizer Inc holds 22.03M shares, accounting for 9.93% of the total shares.
TPG Capital, L.P. holds 18.72M shares, accounting for 8.44% of the total shares.
Citadel Advisors LLC holds 13.35M shares, accounting for 6.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.31M shares, accounting for 5.10% of the total shares.
The Vanguard Group, Inc. holds 8.26M shares, accounting for 3.72% of the total shares.
Pfizer Inc holds 22.03M shares, accounting for 9.93% of the total shares.
TPG Capital, L.P. holds 18.72M shares, accounting for 8.44% of the total shares.
Citadel Advisors LLC holds 13.35M shares, accounting for 6.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.31M shares, accounting for 5.10% of the total shares.
The Vanguard Group, Inc. holds 8.26M shares, accounting for 3.72% of the total shares.
What are the top three shareholder types of Allogene Therapeutics Inc?
The top three shareholder types of Allogene Therapeutics Inc are:
Pfizer Inc
TPG Capital, L.P.
Citadel Advisors LLC
Pfizer Inc
TPG Capital, L.P.
Citadel Advisors LLC
How many institutions hold shares of Allogene Therapeutics Inc (ALLO)?
As of 2025Q4, 373 institutions hold shares of Allogene Therapeutics Inc, with a combined market value of approximately 141.70M, accounting for 82.47% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.96%.
What is the biggest source of revenue for Allogene Therapeutics Inc?
In --, the -- business generated the highest revenue for Allogene Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
